In the UK and globally children are suffering unnecessarily because their health needs are routinely left behind in medical research and development (R&D). A new Independent Child-Lens Taskforce on Health Research, Innovation and Investment has launched to address decades of systemic under-investment in children's health R&D. 

  • Just 1.6% of healthcare venture capital is directed towards child health innovation globally. 

  • Children represent 25% of the global population yet their health needs are systemically underserved.

  • Globally, 50% of paediatric medicines used in hospitals are “off-label”, which means they are not officially approved by regulatory authorities, creating safety risks. 

  • Rare diseases disproportionately affect children, but less than 10% of rare disease therapies are tested in paediatric populations. 

Our Taskforce will focus on developing practical, evidence-based recommendations to advance investment in UK paediatric health R&D.

We hope this approach will improve access and outcomes for young patients across the UK.

The Taskforce was launched on 10th July 2026.  With our first face-to-face meeting taking place at the House of Lords in October 2026.

Distinguished members include those from across the UK, Europe, and Internationally.

Contact us to find out more:

Rhian Thomas Turner 
Head of Paediatric Research Operations & Strategy, Cardiff & Vale UHB 
📧 Rhian.thomas-turner@wales.nhs.uk

A group of nine individuals part of The Child-Lens Taskforce standing in front of Millbank House, a historic stone building with an arched doorway and ornate details. The photo was taken outdoors during daytime.